Biomarkers /
IDH1
Overview
IDH1 (isocitrate dehydrogenase 1 (NADP+), soluble) encodes for the isocitrate dehydrogenase [NADP] cytoplasmic protein, an epigenetic modifier. IDH1 is frequently mutated in glioma and acute myeloid leukemia, among other cancer types (PMID: 23558169).
IDH1 is altered in 2.85% of all cancers with anaplastic astrocytoma, oligodendroglioma, astrocytoma, conventional glioblastoma multiforme, and anaplastic oligodendroglioma having the greatest prevalence of alterations [3].
The most common alterations in IDH1 are IDH1 Mutation (2.75%), IDH1 Codon 132 Missense (2.29%), IDH1 R132H (1.45%), IDH1 R132C (0.62%), and IDH1 R132G (0.12%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of IDH1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.